Home    Back

Olaparib    (DrugBank: Olaparib)

2 diseases
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension2
285Fanconi anemia2

86. Pulmonary arterial hypertension    [ 1,083 clinical trials,   667 drugs,   (DrugBank: 122 drugs),   98 drug target genes,   185 drug target pathways]
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 1,083 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03782818
(ClinicalTrials.gov)		November 20, 201917/12/2018Olaparib for PAH: a Multicenter Clinical TrialOlaparib for Pulmonary Arterial Hypertension: a Multicenter Clinical TrialPulmonary Arterial HypertensionDrug: OlaparibLaval UniversityCanadian Institutes of Health Research (CIHR);AstraZenecaRecruiting18 Years75 YearsAll20Phase 1;Phase 2Canada
2NCT03251872
(ClinicalTrials.gov)		October 25, 201813/8/2017Olaparib for PAH: a Pilot StudyOlaparib for Pulmonary Arterial Hypertension: a Pilot Clinical StudyPulmonary Arterial HypertensionDrug: OlaparibLaval UniversityNULLTerminated18 Years75 YearsAll6Early Phase 1Canada

285. Fanconi anemia    [ 56 clinical trials,   111 drugs,   (DrugBank: 31 drugs),   30 drug target genes,   151 drug target pathways]
Searched query = "Fanconi anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 56 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04483544
(ClinicalTrials.gov)		August 10, 202020/7/2020Pembrolizumab and Olaparib in Cervical Cancer PatientsImmunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair PathwayCervical Cancer;Cervical CarcinomaDrug: pembrolizumab;Drug: olaparibBaptist Health South FloridaFlorida Department of Health;Merck Sharp & Dohme Corp.Recruiting18 YearsN/AFemale48Phase 2United States
2NCT04042831
(ClinicalTrials.gov)		June 9, 202029/7/2019Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene MutationsA Phase II Study of Olaparib in Patients With Advanced Biliary Tract Cancer With Aberrant DNA Repair Gene MutationsARID1A Gene Mutation;ATM Gene Mutation;ATR Gene Mutation;Bile Duct Adenocarcinoma;BRCA1 Gene Mutation;BRCA2 Gene Mutation;BRIP1 Gene Mutation;CHEK2 Gene Mutation;EMSY Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;Metastatic Bile Duct Carcinoma;MRE11 Gene Mutation;NBN Gene Mutation;PALB2 Gene Mutation;PTEN Gene Deletion;RAD51 Gene MutationDrug: OlaparibAcademic and Community Cancer Research UnitedNational Cancer Institute (NCI)Recruiting18 YearsN/AAll36Phase 2United States